Astellas, Pfizer agree to co-promote Caduet

More co-promotion for Astellas Pharma. The Japanese company inked a deal with Pfizer to promote the latter's combo cardiovascular drug Caduet. Pfizer will make and sell the drug, which puts the blood-pressure treatment Norvasc and cholesterol drug Lipitor in one tablet. Astellas and Pfizer will promote the drug together; Pfizer will book sales and Astellas will get a fee.

Earlier this month, Astellas made a deal with AstraZeneca to co-promote the asthma drug Symbicort. AstraZeneca is already looking for government approval of the drug in Japan; once it's OK'd for the market, Astellas will handle sales through its already established channels, and the two companies will both promote the product. 

- see the Astellas release

Related Articles:
Astellas reorganizes R&D ops
Astellas drops bid for CV Therapeutics

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.